

Korean startup Seegene unveils blueprint for MDx future

14 January 2022 | News

Seegene's MDx platform integrates proprietary technologies and development know-how that the startup has developed over the last two decades



Seegene Inc, South Korea-based molecular diagnostics (MDx) startup, has unveiled its blueprint for the future and introduced the company's automated, Al-enabled platform with a standard development tool that will empower users to easily develop their own diagnostic assays.

Dr Jong-Yoon Chun, CEO of Seegene has revealed the on-site screening solution for mass testing with its fully automated MDx system at various facilities including schools, airports, workplaces, and others. It provides a short turnaround time, economic price, and improved accuracy even for asymptomatic cases, which cannot be detected by rapid antigen tests.

The second development is Seegene's centralized screening system, with its newly developed diagnostic test that can multiply the test capacity without additional instrument investments in the laboratories.

And the third is syndromic testing for patients with respiratory symptoms. Seegene had already introduced Allplex[™] RV Master Assay that can simultaneously differentiate ten targets including COVID-19, Flu, and common respiratory viruses. This assay is the key to open a path towards normalcy as it identifies the exact cause of respiratory symptoms.